Indication
Treatment of HLA-A*02:01-positive adult patients with advanced (unresectable or metastatic) uveal melanoma.
Medicine details
- Medicine name:
- tebentafusp (Kimmtrak)
- SMC ID:
- SMC2746
- Pharmaceutical company
- Immunocore Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 07 April 2025
- SMC meeting date:
- 04 March 2025
- Patient group submission deadline:
- 03 February 2025